Abstract: An object of the present invention is to provide a coil component in which leakage of magnetic flux from a magnetic gap is reduced. A coil component includes: a drum-shaped core 20 having a winding core part 30 with a gap G formed therein and first and second flange parts 31 and 32; a plate-like core 40 fixed to the first and second flange parts 31 and 32; and wires W1 to W3 wound around the winding core part 30 and each having one end connected to a terminal electrode provided on the first flange part 31 and the other end connected to a terminal electrode provided on the second flange part 32. According to the present invention, the gap G formed in the winding core part 30 functions as a magnetic gap, and magnetic flux leaking from the magnetic gap is shielded by the plate-like core 40.

Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Abstract: Disclosed herein is a coil component that includes: a first core having a mounting surface and a coil placing surface positioned opposite to the mounting surface; a lower coil placed on the coil placing surface such that a coil axis of the lower coil extends substantially perpendicular to the coil placing surface; an upper coil substantially coaxially stacked on the lower coil; and a second core disposed through inner diameter areas of the lower and upper coils. The number of turns of one of the lower and upper coils is larger by less than one turn than other one of the lower and upper coils. The diameter of the second core is larger at a first section surrounded by the other one of the lower and upper coils than at a second section surrounded by the one of the lower and upper coils.

Abstract: Disclosed herein is a coil component that includes: a first core having a mounting surface and a coil placing surface positioned opposite to the mounting surface; a lower coil placed on the coil placing surface such that a coil axis of the lower coil extends substantially perpendicular to the coil placing surface, the lower coil having one end drawn to a first area of the mounting surface and other end drawn to a second area of the mounting surface; and an upper coil substantially coaxially stacked on the lower coil, the upper coil having one end drawn to a third area of the mounting surface and other end drawn to a fourth area of the mounting surface. The lower coil is greater in a coil diameter than the upper coil.

Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Abstract: An object of the present invention is to provide a coil component in which leakage of magnetic flux from a magnetic gap is reduced. A coil component includes: a drum-shaped core 20 having a winding core part 30 with a gap G formed therein and first and second flange parts 31 and 32; a plate-like core 40 fixed to the first and second flange parts 31 and 32; and wires W1 to W3 wound around the winding core part 30 and each having one end connected to a terminal electrode provided on the first flange part 31 and the other end connected to a terminal electrode provided on the second flange part 32. According to the present invention, the gap G formed in the winding core part 30 functions as a magnetic gap, and magnetic flux leaking from the magnetic gap is shielded by the plate-like core 40.

Abstract: Disclosed herein is a coil component that includes: a first core having a mounting surface and a coil placing surface positioned opposite to the mounting surface; a lower coil placed on the coil placing surface such that a coil axis of the lower coil extends substantially perpendicular to the coil placing surface, the lower coil having one end drawn to a first area of the mounting surface and other end drawn to a second area of the mounting surface; and an upper coil substantially coaxially stacked on the lower coil, the upper coil having one end drawn to a third area of the mounting surface and other end drawn to a fourth area of the mounting surface. The lower coil is greater in a coil diameter than the upper coil.

Abstract: Disclosed herein is a coil component that includes: a first core having a mounting surface and a coil placing surface positioned opposite to the mounting surface; a lower coil placed on the coil placing surface such that a coil axis of the lower coil extends substantially perpendicular to the coil placing surface; an upper coil substantially coaxially stacked on the lower coil; and a second core disposed through inner diameter areas of the lower and upper coils. The number of turns of one of the lower and upper coils is larger by less than one turn than other one of the lower and upper coils. The diameter of the second core is larger at a first section surrounded by the other one of the lower and upper coils than at a second section surrounded by the one of the lower and upper coils.

Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Abstract: A curable silicone composition for the production of composite soft magnetic materials comprising at least (A) a curable organopolysiloxane, (B) a curing agent, (C) a soft magnetic powder, and (D) an organosiloxane represented by the general formula: {R1aR2(3?a)SiO(R22SiO)n}bSiR2{4?(b+c)}(OR3)c wherein R1 is a monovalent hydrocarbon group having at lease one aliphatic unsaturated bond, R2 is the same as R1 or a different monovalent hydrocarbon group having no aliphatic unsaturated bonds, R3 is an alkyl group or an alkoxyalkyl group, the subscript <<a>> is an integer from 1 to 3, the subscript <<b>> is an integer from 1 to 3, the subscript <<c>> is an integer from 1 to 3, the subscript <<b+c>> is an integer from 2 to 4 and the subscript <<n>> is an integer of 0 or greater), as well as composite soft magnetic materials obtained by curing said composition.

Abstract: A CO.sub.2 gas laser device comprises a plurality of divided cathode electrodes disposed in a linear row extending transversely across a high-speed flow of a gas containing CO.sub.2, and parts of the cathode electrodes producing negative glow are disposed at the same height as anodes at a downstream position. Additionally, a device for controlling the distribution of gas flow velocity, which functions doubly as means for creating turbulent flow, and a preliminary discharge electrode are disposed on the upstream side of the cathode electrodes, the former being set at a height position corresponding substantially to that of the middle portions of the cathode electrodes.

Abstract: An ozonizer which comprises a flat hollow metal grounded electrode and a discharge electrode plate spaced apart therefrom by a discharge space. The discharge electrode plate includes a flat hollow dielectric member, a high voltage electrode formed on the inner surface of the dielectric member, a spacer material provided within and held in a clamped state by the dielectric member, a lead conductor provided within and held in a clamped state by the spacer material and a connector connecting the lead conductor and high voltage electrode.